A Gap in the Data: How Clinical Trials Fail to Represent Young and Female Patients
A systematic analysis of 458 new drugs approved by the FDA between 2011 and 2022 reveals a significant mismatch between clinical trial participants and the real-world populations who will use the medications. The study, published in Clinical Pharmacology & Therapeutics, found that trial populations were, on average, 4.8 years younger and had a 4.3 percentage point lower female ratio than the target patient populations for those drugs. The disparity is not uniform across all age groups; for diseases primarily affecting patients under 40, trials actually enrolled older participants, while for conditions in patients aged 50 and older, female representation was significantly lower.
Why it might matter to you: For pediatricians and specialists in adolescent medicine, this research underscores a critical evidence gap in pediatric pharmacology and drug safety. When trials for conditions affecting younger populations enroll older participants, the resulting safety and efficacy data may not accurately predict outcomes for children and adolescents. This has direct implications for clinical decision-making, prescribing practices, and the management of adverse events in your youngest patients, highlighting the need for more age-appropriate trial design.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
